PMID: 11604576Oct 18, 2001Paper

Correction of genetic blood defects by gene transfer

Current Opinion in Hematology
M Cavazzana-Calvo, S Hacein-Bey-Abina

Abstract

Recent clinical trials in patients with a severe combined immunodeficiency disease demonstrate that gene therapy is a powerful tool in the treatment of genetic blood defects. Recent identification of the genes involved in the pathogenesis of inherited lymphohemopoietic disorders led to animal models of gene transfer. Extensive preclinical studies have overcome some of the obstacles involved in the transduction of hemopoietic cells. These promising results led to the approval of several clinical trials that are currently underway. This review focuses on the clinical outcome in patients with genetic blood defects treated by gene transfer and examines the progress achieved to date and the problems that have been encountered. Despite the obstacles, improved clinical results for several of these diseases are expected within the next 5 years.

References

Jul 18, 1995·Proceedings of the National Academy of Sciences of the United States of America·M SadelainR C Mulligan
Jan 19, 1995·The New England Journal of Medicine·C L MackallS M Steinberg
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·J P DiSantoK Rajewsky
Oct 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·H L MalechJ I Gallin
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·L JinC A Blau
Aug 26, 1998·Proceedings of the National Academy of Sciences of the United States of America·P B RobbinsD B Kohn
Feb 18, 1999·The New England Journal of Medicine·R H BuckleyF E Ward
Mar 31, 1999·Immunology Today·T R MalekY W He
Aug 17, 1999·Current Opinion in Immunology·L D NotarangeloK Schwarz
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·M A Kay, K High
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·T VandenDriesscheM K Chuah
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·M BurtonL Couto
Apr 28, 2000·Science·M Cavazzana-CalvoA Fischer
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·M OtsuF Candotti
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·L WangI M Verma
Aug 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·L DumoutierJ C Renauld
Oct 31, 2000·Current Opinion in Hematology·M SadelainI Rivière
Nov 4, 2000·The New England Journal of Medicine·R H Buckley
Nov 25, 2000·Clinical and Experimental Immunology·A Fischer
Feb 24, 2001·Ryōikibetsu shōkōgun shirīzu·M Iwata, H Nunoi
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·J J GregoryA D Auerbach

❮ Previous
Next ❯

Citations

Mar 28, 2006·Langenbeck's Archives of Surgery·Joerg HeroldRuediger C Braun-Dullaeus

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.